Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis

Savino Bruno, Mitchell L. Shiffman, Stuart K. Roberts, Edward J. Gane, Diethelm Messinger, Stephanos J. Hadziyannis, Patrick Marcellin

Research output: Contribution to journalArticle

Abstract

The objective of this study is to determine the efficacy and safety of peginterferon alfa-2a (40KD)/ribavirin in patients with advanced fibrosis. Data from 341 genotype 1/4 patients (99 with bridging fibrosis/cirrhosis) treated for 48 weeks and 1547 genotype 2/3 patients (380 with bridging fibrosis/cirrhosis) treated for 16 or 24 weeks enrolled in three randomized international studies were analyzed. Sustained virological response (SVR) rates decreased progressively from 60% in genotype 1/4 patients without advanced fibrosis to 51% in those with bridging fibrosis and 33% in those with cirrhosis (trend test P = 0.0028); and from 76% to 61% and 57%, respectively, in genotype 2/3 patients treated for 24 weeks (trend test P <0.0001). Irrespective of genotype, patients without advanced fibrosis were more likely to have an earlier response to treatment that was associated with higher SVR rates and lower relapse rates during untreated follow-up. Among patients with or without a diagnosis of advanced fibrosis, rates of SVR and relapse were similar for patients with similar responses in the first 12 weeks. Conclusion: Compared with patients with less severe disease, SVR rates are significantly lower in patients with advanced fibrosis. However, irrespective of genotype and degree of fibrosis, the time to become hepatitis C virus (HCV) RNA undetectable was the strongest predictor of SVR.

Original languageEnglish
Pages (from-to)388-397
Number of pages10
JournalHepatology
Volume51
Issue number2
DOIs
Publication statusPublished - Feb 2010

Fingerprint

Ribavirin
Hepatitis C
Fibrosis
Safety
Genotype
peginterferon alfa-2a
Recurrence
Hepacivirus
RNA

ASJC Scopus subject areas

  • Hepatology

Cite this

Bruno, S., Shiffman, M. L., Roberts, S. K., Gane, E. J., Messinger, D., Hadziyannis, S. J., & Marcellin, P. (2010). Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis. Hepatology, 51(2), 388-397. https://doi.org/10.1002/hep.23340

Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis. / Bruno, Savino; Shiffman, Mitchell L.; Roberts, Stuart K.; Gane, Edward J.; Messinger, Diethelm; Hadziyannis, Stephanos J.; Marcellin, Patrick.

In: Hepatology, Vol. 51, No. 2, 02.2010, p. 388-397.

Research output: Contribution to journalArticle

Bruno, S, Shiffman, ML, Roberts, SK, Gane, EJ, Messinger, D, Hadziyannis, SJ & Marcellin, P 2010, 'Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis', Hepatology, vol. 51, no. 2, pp. 388-397. https://doi.org/10.1002/hep.23340
Bruno, Savino ; Shiffman, Mitchell L. ; Roberts, Stuart K. ; Gane, Edward J. ; Messinger, Diethelm ; Hadziyannis, Stephanos J. ; Marcellin, Patrick. / Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis. In: Hepatology. 2010 ; Vol. 51, No. 2. pp. 388-397.
@article{66dedd4f1c964d17861ca201104b755f,
title = "Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis",
abstract = "The objective of this study is to determine the efficacy and safety of peginterferon alfa-2a (40KD)/ribavirin in patients with advanced fibrosis. Data from 341 genotype 1/4 patients (99 with bridging fibrosis/cirrhosis) treated for 48 weeks and 1547 genotype 2/3 patients (380 with bridging fibrosis/cirrhosis) treated for 16 or 24 weeks enrolled in three randomized international studies were analyzed. Sustained virological response (SVR) rates decreased progressively from 60{\%} in genotype 1/4 patients without advanced fibrosis to 51{\%} in those with bridging fibrosis and 33{\%} in those with cirrhosis (trend test P = 0.0028); and from 76{\%} to 61{\%} and 57{\%}, respectively, in genotype 2/3 patients treated for 24 weeks (trend test P <0.0001). Irrespective of genotype, patients without advanced fibrosis were more likely to have an earlier response to treatment that was associated with higher SVR rates and lower relapse rates during untreated follow-up. Among patients with or without a diagnosis of advanced fibrosis, rates of SVR and relapse were similar for patients with similar responses in the first 12 weeks. Conclusion: Compared with patients with less severe disease, SVR rates are significantly lower in patients with advanced fibrosis. However, irrespective of genotype and degree of fibrosis, the time to become hepatitis C virus (HCV) RNA undetectable was the strongest predictor of SVR.",
author = "Savino Bruno and Shiffman, {Mitchell L.} and Roberts, {Stuart K.} and Gane, {Edward J.} and Diethelm Messinger and Hadziyannis, {Stephanos J.} and Patrick Marcellin",
year = "2010",
month = "2",
doi = "10.1002/hep.23340",
language = "English",
volume = "51",
pages = "388--397",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis

AU - Bruno, Savino

AU - Shiffman, Mitchell L.

AU - Roberts, Stuart K.

AU - Gane, Edward J.

AU - Messinger, Diethelm

AU - Hadziyannis, Stephanos J.

AU - Marcellin, Patrick

PY - 2010/2

Y1 - 2010/2

N2 - The objective of this study is to determine the efficacy and safety of peginterferon alfa-2a (40KD)/ribavirin in patients with advanced fibrosis. Data from 341 genotype 1/4 patients (99 with bridging fibrosis/cirrhosis) treated for 48 weeks and 1547 genotype 2/3 patients (380 with bridging fibrosis/cirrhosis) treated for 16 or 24 weeks enrolled in three randomized international studies were analyzed. Sustained virological response (SVR) rates decreased progressively from 60% in genotype 1/4 patients without advanced fibrosis to 51% in those with bridging fibrosis and 33% in those with cirrhosis (trend test P = 0.0028); and from 76% to 61% and 57%, respectively, in genotype 2/3 patients treated for 24 weeks (trend test P <0.0001). Irrespective of genotype, patients without advanced fibrosis were more likely to have an earlier response to treatment that was associated with higher SVR rates and lower relapse rates during untreated follow-up. Among patients with or without a diagnosis of advanced fibrosis, rates of SVR and relapse were similar for patients with similar responses in the first 12 weeks. Conclusion: Compared with patients with less severe disease, SVR rates are significantly lower in patients with advanced fibrosis. However, irrespective of genotype and degree of fibrosis, the time to become hepatitis C virus (HCV) RNA undetectable was the strongest predictor of SVR.

AB - The objective of this study is to determine the efficacy and safety of peginterferon alfa-2a (40KD)/ribavirin in patients with advanced fibrosis. Data from 341 genotype 1/4 patients (99 with bridging fibrosis/cirrhosis) treated for 48 weeks and 1547 genotype 2/3 patients (380 with bridging fibrosis/cirrhosis) treated for 16 or 24 weeks enrolled in three randomized international studies were analyzed. Sustained virological response (SVR) rates decreased progressively from 60% in genotype 1/4 patients without advanced fibrosis to 51% in those with bridging fibrosis and 33% in those with cirrhosis (trend test P = 0.0028); and from 76% to 61% and 57%, respectively, in genotype 2/3 patients treated for 24 weeks (trend test P <0.0001). Irrespective of genotype, patients without advanced fibrosis were more likely to have an earlier response to treatment that was associated with higher SVR rates and lower relapse rates during untreated follow-up. Among patients with or without a diagnosis of advanced fibrosis, rates of SVR and relapse were similar for patients with similar responses in the first 12 weeks. Conclusion: Compared with patients with less severe disease, SVR rates are significantly lower in patients with advanced fibrosis. However, irrespective of genotype and degree of fibrosis, the time to become hepatitis C virus (HCV) RNA undetectable was the strongest predictor of SVR.

UR - http://www.scopus.com/inward/record.url?scp=75449106958&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75449106958&partnerID=8YFLogxK

U2 - 10.1002/hep.23340

DO - 10.1002/hep.23340

M3 - Article

C2 - 19918980

AN - SCOPUS:75449106958

VL - 51

SP - 388

EP - 397

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 2

ER -